Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | MELK | Q14680 | 5/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 5/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924483 | 0.94 | CNR2 (0.49) | PIM1CNR2MELKPTPN11RET | |
| SCHEMBL6928230 | 0.87 | CNR2 (0.45) | CNR2MELKRETMGLL | |
| SCHEMBL6920372 | 0.86 | CNR2 (0.50) | CNR2PTPN11RETMGLL | |
| SCHEMBL6920358 | 0.81 | CNR2 (0.52) | CNR2MELKRETMGLL | |
| SCHEMBL6925625 | 0.81 | MAP4K4 (0.42) | CNR2SYKRETMGLL | |
| SCHEMBL6924929 | 0.81 | CNR2 (0.39) | CNR2SYKMELKRET | |
| SCHEMBL6921878 | 0.81 | CNR2 (0.45) | CNR2SYKMGLL | |
| SCHEMBL6924520 | 0.80 | CNR2 (0.51) | CNR2RETMGLL | |
| SCHEMBL6925929 | 0.79 | CNR2 (0.46) | CNR2RETMGLL | |
| SCHEMBL6927450 | 0.78 | CNR2 (0.49) | CNR2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | PIM1 4661/4885CNR2 122/4885SYK 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.